SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

SEGMENT INFORMATION

NOTE 14 – SEGMENT INFORMATION

The Company has one operating and reporting segment, that develops, manufactures and markets products for the treatment of carotid artery disease and other vascular disease, including the Company’s proprietary CGuard™ stent platform. The Company’s Chief Operating Decision Maker (“CODM”), who is the CEO evaluates the Company’s performance based on its internal reporting which is consistent with the presentation in the Company’s consolidated financial statements. Accordingly, our CODM uses consolidated net income to measure segment profit or loss, allocate resources, and assess performance.

The CODM examines, within each operational function the employee salaries including the bonus and share based compensation. In addition, the CODM examines the clinical trials expenses within the research and development operations.

	Three months ended September 30,						Nine months ended September 30,
	2025			2024			2025			2024
Revenues		2,523			1,810			5,830			5,060
Cost of Revenues:
Material and Labor		1,391			1,209			3,554			3,373
Other cost of revenues		268			187			807			650
Total Cost of Revenues		1,659			1,396			4,361			4,023
Research and development (R&D)
Payroll and Benefits		1,089			715			3,063			2,066
Share based compensation		576			644			1,889			1,795
Clinical trials		1,105			1,289			3,401			3,240
Other R&D		865			1,267			3,175			2,840
Total Research and development		3,635			3,915			11,528			9,941
Selling and marketing (S&M)
Payroll and Benefits		2,975			907			7,732			2,522
Share based compensation		567			277			1,379			791
Other S&M		850			288			2,203			841
Total Selling and marketing		4,392			1,472			11,314			4,154
General and administrative (G&A)
Payroll and Benefits		1,707			889			5,015			2,539
Share based compensation		2,351			1,460			6,051			4,970
Other G&A		1,830			1,140			5,091			3,569
Total General and administrative		5,888			3,489			16,157			11,078
Financial Income, net;		343			572			505			1,305
Segment net Loss		(12,708	)		(7,890	)		(37,025	)		(22,831	)